SCHEMBL24253558

SCHEMBL24253558

CC(C)c1cn2nccc2cc1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
SLC6A2 P23975 2/20 0.39
HTR2B P41595 2/20 0.39
TRPA1 O75762 1/20 0.39
CHRM1 P11229 1/20 0.39
ADRA1A P35348 1/20 0.39
GABRA1 P14867 4/20 0.38
GABRB2 P47870 3/20 0.38
GABRB1 P18505 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
HIF1A Q16665 2/20 0.35
FAAH O00519 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
GABRG2 P18507 1/20 0.35
PTGS1 P23219 1/20 0.35
HTR2C P28335 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24253458 0.86 GABRA1 (0.38) LMNASLC6A2HTR2BTRPA1CHRM1
SCHEMBL27401220 0.84 SLC6A2 (0.31) LMNASLC6A2HTR2BGABRA1GABRB2
SCHEMBL25722795 0.81 LMNA (0.32) LMNA
SCHEMBL24874280 0.78
SCHEMBL17132594 0.77 IRAK4 (0.32) LMNASLC6A2
SCHEMBL17132571 0.76 IRAK4 (0.34)
SCHEMBL25722807 0.76 ADRA2A (0.33) SLC6A2CHRM1
SCHEMBL25064767 0.73 CYP1A2 (0.35) LMNASLC6A2TRPA1CYP1A2CYP3A4
SCHEMBL24882882 0.73 SCN5A (0.30)
SCHEMBL24248985 0.70 LMNA (0.40) LMNASLC6A2HTR2BTRPA1CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-26 US disclosed
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING RBM17, SF3B1, SF3B5 LMNA 301/4885SLC6A2 4676/4885HTR2B 4365/4885
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.